FD
4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
$13.17 -3.80% (-$0.52)
1M +15.79%
Market Cap $705.2M
P/E Ratio -
Div. Yield -
ROE 41.33%
Bulios Fair Price
$8.95
32.0% downside
Current Price
$13.17
Undervalued Fair Value Overvalued
According to Bulios Fair Price, FDMT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
51 /100
Fair P/S 7.66x
P/B 1.73x
P/E N/A
Growth
100 /100
Growing Rev. growth 200.86%
Book val. growth 29.78%
EPS growth N/A
Profitability
17 /100
Weak Gross margin 42.00%
Net margin 194.74%
FCF margin 170.27%
Quality
2 /100
Poor ROIC 43.77%
ROE 41.33%
Asset turnover 0.19x
Debt
100 /100
Low Debt/Equity 0.10x
Current ratio 8.03x
Int. coverage N/A
Stability
27 /100
Unstable Beta 2.69x
Rev. volatility 132,769.82%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FDMT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David H. Kirn
Employees
196
Headquarters
EmeryVille
Upcoming events
10 NOV
Earnings
Upcoming earnings report